Cardiol Therapeutics (CRDL) Liabilities and Shareholders Equity (2020 - 2026)

Cardiol Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $22.9 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 29.1% year-over-year to $22.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.6 million (down 12.38% YoY) and the FY2025 annual result came in at $16.9 million, down 25.74% from the prior year.
• Liabilities and Shareholders Equity was $22.9 million for Q1 2026 at Cardiol Therapeutics, up from $16.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $62.7 million in Q1 2022 and bottomed at $9.4 million in Q3 2025.
• A 5-year average of $30.1 million and a median of $23.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 107.93% — and 2024, when it tumbled 60.01%.
• Cardiol Therapeutics' Liabilities and Shareholders Equity stood at $45.7 million in 2022, then plunged by 41.01% to $27.0 million in 2023, then retreated by 15.39% to $22.8 million in 2024, then decreased by 25.74% to $16.9 million in 2025, then surged by 35.21% to $22.9 million in 2026.
• Business Quant data shows CRDL's Liabilities and Shareholders Equity at $22.9 million in Q1 2026, $16.9 million in Q4 2025, and $9.4 million in Q3 2025.